SSII
BEARISH
$4.89
Live
SS Innovations International, Inc. · NASDAQ
$3.02
52W Range
$22.42
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$978.64M
P/E
N/A
ROE
-46.9%
Profit margin
-28.5%
Debt/Equity
0.38
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
SSII exhibits critical financial instability, highlighted by a Piotroski F-Score of 0/9, indicating failure across all fundamental health markers. While the company shows explosive revenue growth (79.1% YoY), this is decoupled from profitability, with a net profit margin of -28.54% and a severe valuation disconnect (P/S of 23.04). The stock is in a clear technical downtrend, having lost nearly 50% of its value in the last six months. Without a path to profitability or a correction in valuation, the current price is unsustainable.
Key Strengths
Exceptional YoY revenue growth of 79.10%
Strong Q/Q revenue acceleration of 158.45%
Healthy gross margin of 46.00%
Low Debt/Equity ratio of 0.38
Adequate current ratio of 1.86
Key Risks
Critical financial health failure (Piotroski F-Score 0/9)
Extreme overvaluation with a Price/Book of 24.82 and Price/Sales of 23.04
Negative profitability (ROE -46.94%, Profit Margin -28.54%)
Severe bearish price momentum (-49.8% in 6 months)
Complete lack of analyst coverage and earnings visibility
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
5
65
20
10
0
AI Verdict
High-Risk Speculative
Key drivers: Extreme valuation premium, Zero Piotroski health score, Strong top-line growth
Confidence
90%
Value
5/100
No Graham Number available due to negative earnings; valuation is purely speculative.
Positives
No standout positives identified.
Watchpoints
- P/S of 23.04 is excessive for the industry
- P/B of 24.82 indicates massive premium over book value
Future
65/100
Growth is the only bullish driver, but it is currently inefficient.
Positives
- Hyper-growth in revenue
- Strong market demand indicated by Q/Q growth
Watchpoints
- Unable to convert revenue growth into operating profit
Past
20/100
Recent price action reflects a sharp correction from previous peaks.
Positives
- Long term 5Y change is positive
Watchpoints
- Catastrophic 6-month price decline
- Failure to meet earnings expectations
Health
10/100
The 0/9 F-Score is a definitive signal of fundamental weakness.
Positives
- Low leverage (Debt/Equity 0.38)
Watchpoints
- Piotroski F-Score 0/9
- Negative ROE and ROA
Dividend
0/100
Company is in a growth/burn phase.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.89
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SSII and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SSII
SS Innovations International, Inc.
Primary
|
+22.2% | +22.2% | -44.1% | -49.8% | -3.9% | +13.7% |
|
EVO
Evotec SE
Peer
|
-85.8% | -75.5% | -11.5% | -32.4% | -11.2% | +5.9% |
|
CLOV
Clover Health Investments, Corp.
Peer
|
-78.5% | +126.7% | -40.8% | -29.6% | -5.0% | +8.0% |
|
PHAT
Phathom Pharmaceuticals, Inc.
Peer
|
-65.2% | +21.0% | +198.5% | -5.3% | +16.2% | -0.2% |
|
ASTH
Astrana Health, Inc.
Peer
|
-19.7% | -41.8% | -41.4% | -36.4% | -7.6% | +2.4% |
SSI
SS Innovations International, Inc.
Primary
5Y
+22.2%
3Y
+22.2%
1Y
-44.1%
6M
-49.8%
1M
-3.9%
1W
+13.7%
EVO
Evotec SE
Peer
5Y
-85.8%
3Y
-75.5%
1Y
-11.5%
6M
-32.4%
1M
-11.2%
1W
+5.9%
CLO
Clover Health Investments, Corp.
Peer
5Y
-78.5%
3Y
+126.7%
1Y
-40.8%
6M
-29.6%
1M
-5.0%
1W
+8.0%
PHA
Phathom Pharmaceuticals, Inc.
Peer
5Y
-65.2%
3Y
+21.0%
1Y
+198.5%
6M
-5.3%
1M
+16.2%
1W
-0.2%
AST
Astrana Health, Inc.
Peer
5Y
-19.7%
3Y
-41.8%
1Y
-41.4%
6M
-36.4%
1M
-7.6%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
24.82
P/S Ratio
23.04
EV/Revenue
22.63
EV/EBITDA
-135.09
Market Cap
$978.64M
Profitability
Profit margins and return metrics
Profit Margin
-28.54%
Operating Margin
-5.06%
Gross Margin
46.0%
ROE
-46.94%
ROA
-8.78%
Growth
Revenue and earnings growth rates
Revenue Growth
+79.1%
Earnings Growth
N/A
Q/Q Revenue Growth
+158.45%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.38
Low debt
Current Ratio
1.86
Good
Quick Ratio
0.82
Poor
Cash/Share
$0.02
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
43.9%
Op. Margin
-5.1%
Net Margin
-17.0%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.94x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
213%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-14
$N/A
Healthcare Sector Comparison
Comparing SSII against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-46.94%
This Stock
vs
-97.91%
Sector Avg
-52.1%
(Below Avg)
Profit Margin
-28.54%
This Stock
vs
-16.16%
Sector Avg
+76.6%
(Superior)
Debt to Equity
0.38
This Stock
vs
3.0
Sector Avg
-87.5%
(Less Debt)
Revenue Growth
79.1%
This Stock
vs
142.9%
Sector Avg
-44.6%
(Slower)
Current Ratio
1.86
This Stock
vs
4.65
Sector Avg
-60.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SSII
SS Innovations International, Inc.
|
BEARISH | $978.64M | - | -46.9% | -28.5% | $4.89 | |
|
EVO
Evotec SE
|
BEARISH | $963.68M | - | -18.0% | -21.0% | $2.69 | Compare |
|
CLOV
Clover Health Investments, Corp.
|
BEARISH | $996.87M | - | -26.3% | -4.4% | $1.9 | Compare |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
BULLISH | $1.0B | - | -% | -126.3% | $12.61 | Compare |
|
ASTH
Astrana Health, Inc.
|
BEARISH | $1.02B | 107.0 | 1.8% | 0.3% | $20.33 | Compare |
SSII
SS Innovations...
BEARISH
Mkt Cap
$979M
P/E
-
ROE
-46.9%
Price
$4.89
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-14 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 10,000 | - |
| 2026-04-01 | COHEN BARRY F | Officer and Director | Gift | 7,000 | - |
| 2026-03-30 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 246,000 | - |
| 2026-03-25 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 10,000 | - |
| 2026-03-06 | MOLL FREDERIC H | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 501,253 | $1,999,999 |
| 2026-03-06 | SUDHIR SRIVASTAVA | Chief Executive Officer | Purchase | 498,753 | $2,000,000 |
| 2026-03-06 | ADAMS TIMOTHY P | Director | Purchase | 300,000 | $1,197,000 |
| 2026-02-20 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 2,000,000 | - |
| 2025-12-30 | COHEN BARRY F | Officer and Director | Gift | 28,500 | - |
| 2025-12-30 | COHEN BARRY F | Officer and Director | Gift | 25,500 | - |
| 2025-11-28 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 10,000 | - |
| 2025-11-05 | SUDHIR SRIVASTAVA | Chief Executive Officer | Gift | 30,000 | - |
SUDHIR SRIVASTAVA
Chief Executive Officer
2026-04-14
10,000 shares
COHEN BARRY F
Officer and Director
2026-04-01
7,000 shares
SUDHIR SRIVASTAVA
Chief Executive Officer
2026-03-30
246,000 shares
SUDHIR SRIVASTAVA
Chief Executive Officer
2026-03-25
10,000 shares
MOLL FREDERIC H
Director and Beneficial Owner of more than 10% of a Class of Security
2026-03-06
501,253 shares
·
$1,999,999
SUDHIR SRIVASTAVA
Chief Executive Officer
2026-03-06
498,753 shares
·
$2,000,000
ADAMS TIMOTHY P
Director
2026-03-06
300,000 shares
·
$1,197,000
SUDHIR SRIVASTAVA
Chief Executive Officer
2026-02-20
2,000,000 shares
COHEN BARRY F
Officer and Director
2025-12-30
28,500 shares
COHEN BARRY F
Officer and Director
2025-12-30
25,500 shares
SUDHIR SRIVASTAVA
Chief Executive Officer
2025-11-28
10,000 shares
SUDHIR SRIVASTAVA
Chief Executive Officer
2025-11-05
30,000 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
10-K
S-1
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning SSII from our newsroom.
Newest → oldest
No matching news yet.